Home Physical Sciences Crystal structure of 4-((E)-((E)-5-(2-fluorobenzylidene)-1-((4-fluorophenyl)sulfonyl)-4-oxopiperidin-3-ylidene)methyl)benzonitrile, C26H18F2N2O3S
Article Open Access

Crystal structure of 4-((E)-((E)-5-(2-fluorobenzylidene)-1-((4-fluorophenyl)sulfonyl)-4-oxopiperidin-3-ylidene)methyl)benzonitrile, C26H18F2N2O3S

  • Lian-Dong Liu EMAIL logo , Shu-Lian Liu and Gui-Ge Hou
Published/Copyright: July 31, 2018
Download Article (PDF)
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Zeitschrift für Kristallographie - New Crystal Structures
From the journal Zeitschrift für Kristallographie - New Crystal Structures Volume 233 Issue 6

Abstract

C26H18F2N2O3S, monoclinic, P21/c (no. 14), a = 8.412(3) Å, b = 22.056(8) Å, c = 12.125(4) Å, β = 102.316(5)°, V = 2198.0(14) Å3, Z = 4, Rgt(F) = 0.0475, wRref(F2) = 0.1156, T = 173(2) K.

CCDC no.: 1856746

The crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Yellow block
Size:0.26 × 0.25 × 0.05 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.20 mm−1
Diffractometer, scan mode:Bruker SMART, φ and ω-scans
θmax, completeness:25.5°, >99%
N(hkl)measured, N(hkl)unique, Rint:11378, 4095, 0.034
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 3110
N(param)refined:307
Programs:Bruker programs [1], SHELX [2, 3]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
F10.39138(19)0.69104(6)0.33479(12)0.0567(4)
F20.6284(2)0.67176(7)−0.07671(13)0.0642(5)
N10.9098(2)0.49932(8)0.36203(14)0.0287(4)
N21.0896(3)0.18516(11)−0.0654(2)0.0623(7)
O10.47692(18)0.51400(7)0.14691(13)0.0376(4)
O21.13701(19)0.50701(8)0.26644(15)0.0496(5)
O31.0843(2)0.58965(8)0.39257(14)0.0477(5)
S11.02532(7)0.54487(3)0.30837(5)0.03483(17)
C10.5109(2)0.61043(9)0.45075(18)0.0282(5)
C20.4474(3)0.66868(10)0.4410(2)0.0370(6)
C30.4388(3)0.70506(12)0.5313(2)0.0455(6)
H30.39530.74490.52030.055*
C40.4952(3)0.68229(12)0.6391(2)0.0464(7)
H40.48960.70650.70290.056*
C50.5594(3)0.62475(11)0.6538(2)0.0417(6)
H50.59790.60930.72780.050*
C60.5677(3)0.58948(10)0.56101(18)0.0341(5)
H60.61330.55000.57240.041*
C70.5110(3)0.57439(9)0.34961(17)0.0279(5)
H70.41900.57900.28930.033*
C80.6254(2)0.53571(9)0.33204(17)0.0250(5)
C90.5941(2)0.50182(9)0.22258(18)0.0270(5)
C100.7093(2)0.45183(9)0.20863(17)0.0273(5)
C110.8562(3)0.44224(9)0.30376(18)0.0320(5)
H11A0.82860.41280.35850.038*
H11B0.94630.42500.27290.038*
C120.7842(2)0.52497(10)0.41614(17)0.0301(5)
H12A0.82360.56390.45280.036*
H12B0.76480.49690.47560.036*
C130.6782(3)0.42130(9)0.11060(18)0.0290(5)
H130.58590.43450.05640.035*
C140.7683(3)0.37020(9)0.07624(18)0.0295(5)
C150.7667(3)0.36228(9)−0.03809(18)0.0301(5)
H150.70670.3897−0.09160.036*
C160.8503(3)0.31550(10)−0.07497(19)0.0331(5)
H160.84810.3109−0.15320.040*
C170.9383(3)0.27491(10)0.00278(19)0.0348(5)
C180.9386(3)0.28133(10)0.1174(2)0.0425(6)
H180.99720.25340.17060.051*
C190.8538(3)0.32810(10)0.1533(2)0.0393(6)
H190.85330.33190.23130.047*
C201.0241(3)0.22505(11)−0.0344(2)0.0428(6)
C210.9050(3)0.58326(9)0.19160(18)0.0301(5)
C220.8874(3)0.55904(10)0.08393(19)0.0367(5)
H220.94070.52220.07310.044*
C230.7924(3)0.58846(11)−0.0074(2)0.0418(6)
H230.77860.5724−0.08160.050*
C240.7188(3)0.64138(11)0.0126(2)0.0427(6)
C250.7324(3)0.66633(11)0.1182(2)0.0422(6)
H250.67830.70310.12820.051*
C260.8265(3)0.63652(10)0.20921(19)0.0348(5)
H260.83740.65240.28330.042*

Source of material

N-Methyl-4-piperidone (1.14 g, 0.01 mol), 2-fluorobenzaldehyde (1.24 mol, 0.01 mol) and 4-cyanobenzaldehyde (1.31 g, 0.01 mol) were dissolved in 15 mL of acetic acid. Dry HCl gas was passed through this mixture for 25 min. After stirring at room temperature for about 24 h, the mixture was added into 100 mL water, and then aqueous NaOH solution was added until the pH was adjusted to about 7. The mixture was filtered and subsequently washed by water to provide a yellow precipitate. The precipitates were purified on silica gel by column using methanol/petroleum ether/EtOAc (10:10:1, v/v/v) as the eluent to afford a yellow intermediate. Then, the yellow intermediate and 4-fluorophenylsulfonylfluoride (1.78 g, 0.01 mol) were dissolved in 50 mL of dichloromethane. Potassium carbonate (2.76 g, 0.02 mol) was added to the mixture and the mixture were stirred for about 12 h at room temperature. The precipitate was collected, washed with water and recrystallized from dichloromethane/methanol (1:1, v/v) to get light yellow crystals of title compound.

Experimental details

All H atoms were placed in idealized positions and treated as riding on their parent atoms, with d(C—H) = 0.99 Å (methylene), Uiso(H) = 1.2Ueq(C) and d(C—H) = 0.95 Å (aromatic), Uiso(H) = 1.2Ueq(C).

Discussion

Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)1,6-hepta-dien-3,5-dion) has proved to be a powerful chemopreventive and anticancer agent, including anti-inflammatory, antibacterial, and antioxidant properties. However, the clinical use of curcumin has been limited because of its low anticancer activity and poor bioavailability [4]. In order to improve these defects, a novel class of curcumin analogues, (3E,5E)-3,5-bis(arylidene)-4-piperidone derivatives, has been reported as better antitumor agents [5], [6], [7], [8]. Its pharmacophore is 1,5-diaryl-3-oxo-1,4-pentadienyl, which contains a α,β-unsaturated keto group and has a greater preference or sequential affinity for bio-thiols in contrast to amino and hydroxy groups resulting in a greater chemosensitivity to tumors rather than with normal cells. Our interests lie in incorporation of different substituent groups on both sides of (3E,5E)-3,5-bis(arylidene)-4-piperidone. In addition, N-benzenesulfonyl substituents should improve antitumor activities and anti-inflammatory activity [9], [10], [11], [12], [13]. In this study, we report herein the crystal structure of 4-((E)-((E)-5-(2-fluorobenzylidene)-1-((4-fluorophenyl)sulfonyl)-4-oxopiperidin-3-ylidene)methyl)benzonitrile.

There is one molecule in the asymmetric unit of the title crystal structure (cf. the figure). Bond lengths and angles are all in the expected ranges. Derived from the crystal structure deterimination we learned that the C1—C7—C8—C9 torsion angle value is 177.29(3)° and the C9—C10—C13—C14 torsion angle value is 178.64(2)°. The 2-fluorophenyl group and the 4-cyano phenyl group on both sides of 3,5-bis(arylidene)-4-piperidone adopt the E stereochemistry of olefinic double bonds and the E, E isomer [14]. The 4-fluorophenyl group is almost coplanar with two substituated aryl rings on both sides of 3,5-bis(arylidene)-4-piperidone, which can be proved by the dihedral angles (12.207(4)° and 13.925(5)°, respectively). On the whole, the title molecule group looks like an “organic clip” [15]. The heteroatoms (F, N, O, S) can act as hydrogen bonding acceptors for biological macromolecules with the aim of creating more potent cytostatica [16].

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 21402010).

References

Bruker.: APEX2, SAINT and SADABS. Brucker AXS Inc., Madison, WI, USA (2009).Search in Google Scholar

Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Search in Google Scholar PubMed

Sheldrick, G. M.: Crystal structure refinement with SHELXL. Acta Crystallogr. C71 (2015) 3–8.10.1107/S2053229614024218Search in Google Scholar PubMed PubMed Central

Nelson, K. M.; Dahlin, J. L.; Bisson, J.; Graham, J.; Pauli, G. F.; Walters. M. A.: The essential medicinal chemistry of curcumin. J. Med. Chem. 60 (2017) 1620–1637.10.1021/acs.jmedchem.6b00975Search in Google Scholar PubMed PubMed Central

Sun, J. F.; Zhang, S. P.; Yu, C.; Hou, G. G.; Zhang, X. F.; Li, K. K.; Zhao, F.: Design, Synthesis and bioevaluation of novel N-substituted-3,5-bis(arylidene)-4-piperidone derivatives as cytotoxic and antitumor agents with fluorescent properties. Chem. Biol. Drug. Des. 83 (2014) 392–400.10.1111/cbdd.12254Search in Google Scholar PubMed

Li, N.; Xin, W. Y.; Yao, B. R.; Wang, C. H.; Cong, W.; Zhao, F.; Li, H. J.; Hou, Y.; Meng, Q. G.; Hou, G. G.: Novel dissymmetric 3,5-bis(arylidene)-4-piperidones as potential antitumor agents with biological evaluation in vitro and in vivo. Eur. J. Med. Chem. 147 (2018) 21–33.10.1016/j.ejmech.2018.01.088Search in Google Scholar PubMed

Zhu, H. P.; Xu, T. T.; Qiu, C. Y.; Wu, B. B.; Zhang, Y. L.; Chen, L. F.; Xia, Q. Q.; Li, C. L.; Zhou, B.; Liu, Z. G.; Liang, G.: Synthesis and optimization of novel allylated mono-carbonyl analogs of curcumin (MACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI) in rats. Eur. J. Med. Chem. 121 (2016) 181–193.10.1016/j.ejmech.2016.05.041Search in Google Scholar PubMed

Yin, D. L.; Liang, Y. J.; Zheng, T. S.; Song, R. P.; Wang, J. B.; Sun, B. S.; Pan, S. H.; Qu, L. D.; Liu, J. R.; Jiang, H. C.; Liu, L. X.: EF24 inhibits tumor growth and metastasis via suppressing NF-kB dependent pathways in human cholangiocarcinoma. Sci. Rep. 6 (2016) 32167.10.1038/srep32167Search in Google Scholar PubMed PubMed Central

Bano, S.; Javed, K.; Ahmad, S.; Rathish, I. G.; Singh, S.; Alam, M. S.: Synthesis and biological evaluation of some new 2-pyrazolines bearing benzene sulfonamide moiety as potential anti-inflammatory and anti-cancer agents. Eur J. Med. Chem. 46 (2011) 5763–5768.10.1016/j.ejmech.2011.08.015Search in Google Scholar PubMed

Bashir, R.; Ovais, S.; Yaseen, S.; Hamid, H.; Alam, M. S.; Samim, M.; Singh, S.; Javed, K.: Synthesis of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide as anticancer and antiinflammatory agents. Bioorg. Med. Chem. Lett. 21 (2011) 4301–4305.10.1016/j.bmcl.2011.05.061Search in Google Scholar PubMed

Antoniou, V.; Tsoukali-Papadopoulou, H.; Epivatianos, P.; Nathanael, B.: Synthesis and pharmacological evaluation of novel 5-substituted-1-(phenylsulfonyl)-2-methylbenzimidazole derivatives as anti-inflammatory and analgesic agents. Eur. J. Med. Chem. 45 (2010) 2245–2249.10.1016/j.ejmech.2010.01.067Search in Google Scholar PubMed

Park, E. B.; Kim, K. J.; Hui, R. J.; Lee, J. K.; Kim, H. J.; Lee, H. H.; Ji, W. L.; Shin, J. S.; Koeberle, A.; Werz, O.: Synthesis, structure determination, and biological evaluation of phenylsulfonyl hydrazide derivatives as potential anti-inflammatory agents. Bioorg. Med. Chem. Lett. 26 (2016) 5193–5197.10.1016/j.bmcl.2016.09.070Search in Google Scholar PubMed

Pinz, M. P.; Reis, A. S.; Oliveira, R. L. D.; Voss, G. T.; Vogt, A. G.; Sacramento, M. D.; Roehrs, J. A.; Alves, D.; Luchese, C.; Wilhelm, E. A.: 7-Chloro-4-phenylsulfonyl quinoline, a new antinociceptive and anti-inflammatory molecule: Structural improvement of a quinoline derivate with pharmacological activity. Regul. Toxicol. Pharm. 90 (2017) 72–77.10.1016/j.yrtph.2017.08.014Search in Google Scholar PubMed

Sun, J. F.; Wang, S. W.; Li, H. J.; Jiang, W. G.; Hou, G. G.; Zhao, F.; Cong, W.: Synthesis, antitumor activity evaluation of some new N-aroyl-α,β-unsaturated piperidones with fluorescence. J. Enzyme Inhib. Med. Chem. 31 (2016) 495–502.10.3109/14756366.2015.1043296Search in Google Scholar PubMed

Hou, G. G.; Zhao, H. J.; Sun, J. F.; Lin, D.; Dai, X. P.; Han, J. T.; Zhao, H.: Synthesis, structure and luminescence of Co-crystals with hexagonal channels: arranging disposition and π-π interactions. CrystEngComm 15 (2012) 577–585.10.1039/C2CE25759ASearch in Google Scholar

Das, U.; Sakagami, H.; Chu, Q.; Wang, Q.; Kawase, M.; Selvakumar, P.; Sharma, R. K.; Dimmock, J. R.: 3,5-Bis(benzylidene)-1-(4-2-(morpholin-4-yl) ethoxyphenylcarbonyl)-4-piperidone hydrochloride: a lead tumor-specific cytotoxin which induces apoptosis and autophagy. Bioorg. Med. Chem. Lett. 20 (2010) 912–917.10.1016/j.bmcl.2009.12.076Search in Google Scholar PubMed PubMed Central

Received: 2018-05-16
Accepted: 2018-07-19
Published Online: 2018-07-31
Published in Print: 2018-11-27

©2018 Lian-Dong Liu et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Articles in the same Issue

  1. Cover and Frontmatter
  2. Crystal structure of di-μ2-aqua-tetraaqua-bis(4-(1H-1,2,4-triazol-1-yl)benzoato-κN)disodium(I) C18H24N6Na2O10
  3. Crystal structure of diaqua-bis(2-bromo-4-chloro-6-formylphenolato-κ2O,O′)cobalt(II), C16H16Cl2CrN3O7
  4. Crystal structure of catena-poly[(μ2-1-(4-(1H-pyrazol-1-yl)phenyl)ethan-1-one-κ2N:O)-bis(1,1,1-trifluoro-4-oxo-4-(thiophen-2-yl)but-2-en-2-olato-κ2O,O′)copper(II)], C27H18CuF6N2O5S2
  5. Crystal structure of ethyl 2-amino-4-(3,5-difluorophenyl)-7-methyl-5-oxo-4H,5H-pyrano[4,3-b]pyran-3-carboxylate, C18H15F2NO5
  6. Crystal structure of 5,5′-dimethoxy-2,2′-[1,1′-(ethylenedioxydinitrilo)diethylidyne]diphenol, C20H24N2O6
  7. Crystal structure of (E)-1-(4-(((E)-3,5-dichloro-2-hydroxybenzylidene)amino)phenyl)ethan-1-one O-methyl oxime, C16H14Cl2N2O2
  8. Crystal structure of 2,3,9,10,16,17,23,24-octakis(2,6-dimethylphenoxy)phthalocyanine - trichloromethane (1/2), C98H84Cl6N8O8
  9. Crystal structure of methyl 2-((1-(2-(methoxycarbonyl)benzyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-naphthoate, C24H21N3O5
  10. Crystal structure of catena-poly[(μ2-3,3′-thiodipropionato-κ2O:O′)-(bipyridine-κ2N,N′)copper(II)] C16H16CuN2O4S
  11. Crystal structure of [4-chloro-2-(((2-((3-ethoxy-2-oxidobenzylidene)amino)phenyl)imino)(phenyl)methyl)phenolato-κ4N,N′,O,O′}nickel(II) - ethyl acetate (1/1), C32H29ClN2NiO5
  12. Crystal structure of (4-(4-chlorophenyl)-5-ethyl-1,3-dioxane-5-carboxylato-κ2O,O′)-(5,5,7,12,12,14-hexamethyl-1,4,8,11-tetraazacyclotetradecane-κ4N,N′,N′′,N′′′)nickel(II) perchlorate monohydrate, C29H52Cl2N4NiO9
  13. Crystal structure of ethyl 2-amino-4-(3,4-dimethylphenyl)-7-methyl-5-oxo-4H,5H-pyrano[4,3-b]pyran-3-carboxylate, C20H21NO5
  14. Structure and photochromism of 1,2-bis[2-methyl-5-(3-quinolyl)-3-thienyl]-3,3,4,4,5,5-hexafluorocyclopent-1-ene, C33H20F6N2S2
  15. Crystal structure of catena-poly[diaqua-bis(μ2-3,5-di(1H-1,2,4-triazol-1-yl)benzoate-κ2N:N′)cobalt(II))] 2.5 hydrate, C22H23CoN12O8.50
  16. The crystal structure of dichlorido(1,3-dimesityl-1H-3λ4-imidazol-2-yl)(morpholine-κN)palladium(IV), C25H33Cl2N3OPd
  17. Crystal structure of catena-poly[bis(4,4′-dipyridylaminium-kN)-(μ2-germanowolframato-κ2O:O′)-(2,2′-bipyridine-κ2N,N′)copper(II)] with a Keggin-type heteropolyoxoanion, [Cu(C10H8N2)(C10H10N3)2][GeW12O40] ⋅ H2O
  18. Crystal structure of diaqua-(N-(1-(pyrazin-2-yl)ethylidene)pyridin-1-ium-4-carbohydrazonate-κ3N,N′,O)-tris[nitrato-κ2O,O′)lanthanum(III), C12H15N8O12La
  19. The crystal structure of 2-hydroxy-4-((2-hydroxy-4-methoxy-3,6-dimethylbenzoyl)oxy)-3,6-dimethylbenzoic acid–methanol (1/1), C20H24O8
  20. Crystal structure of guanidinium tetrapropylammonium bis(hydrogencarbonate) dihydrate, C15H40N4O8
  21. Crystal structure of (Z)-2-bromo-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-phenylprop-2-en-1-one, C23H27BrO2
  22. Crystal structure of 2-(4-(4H-1,2,4-triazol-4-yl)phenyl)acetic acid, C10H9N3O4
  23. Crystal structure of 4,4′-(1,4-phenylene)bis(1H-imidazol-3-ium)bis(2-carboxybenzoate), C30H26N4O8
  24. Crystal structure of 4,4′-(4,10-diphenyl-4,10-dihydropyreno[4,5-d:9,10-d′]diimidazole-5,11-diyl)bis(N,N-diphenylaniline), C66H44N6
  25. Crystal structure of catena-poly[diaqua-bis(μ2-5-(3-(1H-imidazol-5-yl)phenyl)tetrazol-2-ido-κ2N:N′)cobalt(II)], C20H18CoN12O2
  26. Crystal structure of 1,3-dimethyl-2-(p-tolyl)-1H-perimidin-3-ium iodide 1.5 hydrate, C20H22IN2O1.5
  27. Crystal structure of 2-(4-methoxyphenyl)chromane, C16H16O2
  28. Crystal structure of poly[(μ2-2-carboxy-5-nitroisophthalato-κ2O:O′)-(μ2-4-((1H-imidazol-1-yl)methyl)pyridine-κ2N:N′)zinc(II)], C18H12N4O8Zn
  29. Crystal structure of bis(1-((2-ethyl-4-methyl-1H-imidazol-1-yl)methyl)-1H-benzo[d][1,2,3]triazole-κ2N:N′)tetraiodidodicadmium(II), [Cd2(C13H15N5)2I4]
  30. Crystal structure of tetramethylammonium bis(acetato-κ1O)-tetrakis(μ3-3-((hydroxyimino)methyl)-5-methoxy-2-oxidobenzoate-κ5O,O′:O′,N:O′′)tetrazinc(II) — N,N′-dimethylformamide — water (1/2/2), C62H96Zn4N10O28
  31. Crystal structure of poly[(μ4-5-tert-butylisophthalato-κ4O:O′:O′′:O′′′)-(1,3-dimethyl-2-imidazolidinone-κO)zinc(II)] C17H22N2O5Zn
  32. Crystal structure of [tris(2-benzimidazolylmethyl)amine-κ4N,N′,N′′,N′′′]-[(pyridine-2,6-dicarboxylato-κ2O,N)]cadmium(II)–methanol (1:3) C34H36CdN8O7
  33. The crystal structure of bis(1H-benzo[d]imidazol-2-amine-κN)-diiodidocadmium(II), C14H14CdI2N6
  34. Crystal structure of tetrakis(1H-benzimidazol-2-amine)-κN)-bis(μ2-sulfonato-κ2O:O′)dizinc(II) - methanol (1/1), C30H36N12O10S2Zn2
  35. Crystal structure of 3β-methoxy-20α-dimethylamino-pregn-5-ene, C24H41NO
  36. Crystal structure of dimethyl 4,4′-oxydibenzoate, C16H14O5
  37. Crystal structure of catena-poly[diiodido-(μ2-1,5-dimethyl-2-phenyl-4-((pyridin-3-ylmethylene)amino)-1,2-dihydro-3H-pyrazol-3-one-κ2N:O)zinc(II)], C17H16I2N4OZn
  38. Crystal structure of 4-((E)-((E)-5-(2-fluorobenzylidene)-1-((4-fluorophenyl)sulfonyl)-4-oxopiperidin-3-ylidene)methyl)benzonitrile, C26H18F2N2O3S
  39. Crystal structure of bis(acetato-κ1O)-bis(1-(pyridin-2-yl)ethan-1-one oxime-κ2N,N′)zinc(II), C18H22N4O6Zn
  40. The crystal structure of 9-butoxy-2-(hydroxymethyl)-2H-imidazo[1,5-a]quinolin-10-ium bromide, C17H21O2N2Br
  41. Crystal stucture of 2-(tert-butyl)-6-(hydroxymethyl)-4-methylphenol, C12H18O2
  42. Crystal structure of catena-poly[(2-(5-chloroquinolin-8-yloxy)-1-(pyrrolidin-1-yl)ethan-1-one-κ3N,O,O′)-(dinitrato-κ2O,O′)mercury(II)], C15H15N4O8ClHg
  43. Crystal structure of dimethyl (3aS,6R,6aS,7S)-1H,3H,6H,7H-3a,6:7,9a-diepoxybenzo[de]isochromene-3a1,6a-dicarboxylate, C16H16O7
  44. The crystal structure of 2-(dimethoxymethyl)-4-(4-methylphenyl)-1H-imidazole—petroleum ether-chloroform (3/1), C27H33Cl3N4O4
  45. Crystal structure of 8-(trifluoromethyl)imidazo[1,2-a]pyridine-3-carbaldehyde, C9H5F3N2O
  46. The crystal structure of N,N-diethyl-4,6-bis(naphthalen-2-yloxy)-1,3,5-triazin-2-amine, C27H24N4O2
  47. Crystal structure of 5-bromo-7-chloro-3,3a-dihydrocyclopenta[b]chromen-1(2H)-one, C12H8BrClO2
  48. Crystal structure of 2-(bis(4-fluorophenyl)methylene)hydrazine-1-carbothioamide, C14H11F2N3S
https://doi.org/10.1515/ncrs-2018-0174
Creative Commons
BY-NC-ND 4.0

Articles in the same Issue

  1. Cover and Frontmatter
  2. Crystal structure of di-μ2-aqua-tetraaqua-bis(4-(1H-1,2,4-triazol-1-yl)benzoato-κN)disodium(I) C18H24N6Na2O10
  3. Crystal structure of diaqua-bis(2-bromo-4-chloro-6-formylphenolato-κ2O,O′)cobalt(II), C16H16Cl2CrN3O7
  4. Crystal structure of catena-poly[(μ2-1-(4-(1H-pyrazol-1-yl)phenyl)ethan-1-one-κ2N:O)-bis(1,1,1-trifluoro-4-oxo-4-(thiophen-2-yl)but-2-en-2-olato-κ2O,O′)copper(II)], C27H18CuF6N2O5S2
  5. Crystal structure of ethyl 2-amino-4-(3,5-difluorophenyl)-7-methyl-5-oxo-4H,5H-pyrano[4,3-b]pyran-3-carboxylate, C18H15F2NO5
  6. Crystal structure of 5,5′-dimethoxy-2,2′-[1,1′-(ethylenedioxydinitrilo)diethylidyne]diphenol, C20H24N2O6
  7. Crystal structure of (E)-1-(4-(((E)-3,5-dichloro-2-hydroxybenzylidene)amino)phenyl)ethan-1-one O-methyl oxime, C16H14Cl2N2O2
  8. Crystal structure of 2,3,9,10,16,17,23,24-octakis(2,6-dimethylphenoxy)phthalocyanine - trichloromethane (1/2), C98H84Cl6N8O8
  9. Crystal structure of methyl 2-((1-(2-(methoxycarbonyl)benzyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-naphthoate, C24H21N3O5
  10. Crystal structure of catena-poly[(μ2-3,3′-thiodipropionato-κ2O:O′)-(bipyridine-κ2N,N′)copper(II)] C16H16CuN2O4S
  11. Crystal structure of [4-chloro-2-(((2-((3-ethoxy-2-oxidobenzylidene)amino)phenyl)imino)(phenyl)methyl)phenolato-κ4N,N′,O,O′}nickel(II) - ethyl acetate (1/1), C32H29ClN2NiO5
  12. Crystal structure of (4-(4-chlorophenyl)-5-ethyl-1,3-dioxane-5-carboxylato-κ2O,O′)-(5,5,7,12,12,14-hexamethyl-1,4,8,11-tetraazacyclotetradecane-κ4N,N′,N′′,N′′′)nickel(II) perchlorate monohydrate, C29H52Cl2N4NiO9
  13. Crystal structure of ethyl 2-amino-4-(3,4-dimethylphenyl)-7-methyl-5-oxo-4H,5H-pyrano[4,3-b]pyran-3-carboxylate, C20H21NO5
  14. Structure and photochromism of 1,2-bis[2-methyl-5-(3-quinolyl)-3-thienyl]-3,3,4,4,5,5-hexafluorocyclopent-1-ene, C33H20F6N2S2
  15. Crystal structure of catena-poly[diaqua-bis(μ2-3,5-di(1H-1,2,4-triazol-1-yl)benzoate-κ2N:N′)cobalt(II))] 2.5 hydrate, C22H23CoN12O8.50
  16. The crystal structure of dichlorido(1,3-dimesityl-1H-3λ4-imidazol-2-yl)(morpholine-κN)palladium(IV), C25H33Cl2N3OPd
  17. Crystal structure of catena-poly[bis(4,4′-dipyridylaminium-kN)-(μ2-germanowolframato-κ2O:O′)-(2,2′-bipyridine-κ2N,N′)copper(II)] with a Keggin-type heteropolyoxoanion, [Cu(C10H8N2)(C10H10N3)2][GeW12O40] ⋅ H2O
  18. Crystal structure of diaqua-(N-(1-(pyrazin-2-yl)ethylidene)pyridin-1-ium-4-carbohydrazonate-κ3N,N′,O)-tris[nitrato-κ2O,O′)lanthanum(III), C12H15N8O12La
  19. The crystal structure of 2-hydroxy-4-((2-hydroxy-4-methoxy-3,6-dimethylbenzoyl)oxy)-3,6-dimethylbenzoic acid–methanol (1/1), C20H24O8
  20. Crystal structure of guanidinium tetrapropylammonium bis(hydrogencarbonate) dihydrate, C15H40N4O8
  21. Crystal structure of (Z)-2-bromo-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-phenylprop-2-en-1-one, C23H27BrO2
  22. Crystal structure of 2-(4-(4H-1,2,4-triazol-4-yl)phenyl)acetic acid, C10H9N3O4
  23. Crystal structure of 4,4′-(1,4-phenylene)bis(1H-imidazol-3-ium)bis(2-carboxybenzoate), C30H26N4O8
  24. Crystal structure of 4,4′-(4,10-diphenyl-4,10-dihydropyreno[4,5-d:9,10-d′]diimidazole-5,11-diyl)bis(N,N-diphenylaniline), C66H44N6
  25. Crystal structure of catena-poly[diaqua-bis(μ2-5-(3-(1H-imidazol-5-yl)phenyl)tetrazol-2-ido-κ2N:N′)cobalt(II)], C20H18CoN12O2
  26. Crystal structure of 1,3-dimethyl-2-(p-tolyl)-1H-perimidin-3-ium iodide 1.5 hydrate, C20H22IN2O1.5
  27. Crystal structure of 2-(4-methoxyphenyl)chromane, C16H16O2
  28. Crystal structure of poly[(μ2-2-carboxy-5-nitroisophthalato-κ2O:O′)-(μ2-4-((1H-imidazol-1-yl)methyl)pyridine-κ2N:N′)zinc(II)], C18H12N4O8Zn
  29. Crystal structure of bis(1-((2-ethyl-4-methyl-1H-imidazol-1-yl)methyl)-1H-benzo[d][1,2,3]triazole-κ2N:N′)tetraiodidodicadmium(II), [Cd2(C13H15N5)2I4]
  30. Crystal structure of tetramethylammonium bis(acetato-κ1O)-tetrakis(μ3-3-((hydroxyimino)methyl)-5-methoxy-2-oxidobenzoate-κ5O,O′:O′,N:O′′)tetrazinc(II) — N,N′-dimethylformamide — water (1/2/2), C62H96Zn4N10O28
  31. Crystal structure of poly[(μ4-5-tert-butylisophthalato-κ4O:O′:O′′:O′′′)-(1,3-dimethyl-2-imidazolidinone-κO)zinc(II)] C17H22N2O5Zn
  32. Crystal structure of [tris(2-benzimidazolylmethyl)amine-κ4N,N′,N′′,N′′′]-[(pyridine-2,6-dicarboxylato-κ2O,N)]cadmium(II)–methanol (1:3) C34H36CdN8O7
  33. The crystal structure of bis(1H-benzo[d]imidazol-2-amine-κN)-diiodidocadmium(II), C14H14CdI2N6
  34. Crystal structure of tetrakis(1H-benzimidazol-2-amine)-κN)-bis(μ2-sulfonato-κ2O:O′)dizinc(II) - methanol (1/1), C30H36N12O10S2Zn2
  35. Crystal structure of 3β-methoxy-20α-dimethylamino-pregn-5-ene, C24H41NO
  36. Crystal structure of dimethyl 4,4′-oxydibenzoate, C16H14O5
  37. Crystal structure of catena-poly[diiodido-(μ2-1,5-dimethyl-2-phenyl-4-((pyridin-3-ylmethylene)amino)-1,2-dihydro-3H-pyrazol-3-one-κ2N:O)zinc(II)], C17H16I2N4OZn
  38. Crystal structure of 4-((E)-((E)-5-(2-fluorobenzylidene)-1-((4-fluorophenyl)sulfonyl)-4-oxopiperidin-3-ylidene)methyl)benzonitrile, C26H18F2N2O3S
  39. Crystal structure of bis(acetato-κ1O)-bis(1-(pyridin-2-yl)ethan-1-one oxime-κ2N,N′)zinc(II), C18H22N4O6Zn
  40. The crystal structure of 9-butoxy-2-(hydroxymethyl)-2H-imidazo[1,5-a]quinolin-10-ium bromide, C17H21O2N2Br
  41. Crystal stucture of 2-(tert-butyl)-6-(hydroxymethyl)-4-methylphenol, C12H18O2
  42. Crystal structure of catena-poly[(2-(5-chloroquinolin-8-yloxy)-1-(pyrrolidin-1-yl)ethan-1-one-κ3N,O,O′)-(dinitrato-κ2O,O′)mercury(II)], C15H15N4O8ClHg
  43. Crystal structure of dimethyl (3aS,6R,6aS,7S)-1H,3H,6H,7H-3a,6:7,9a-diepoxybenzo[de]isochromene-3a1,6a-dicarboxylate, C16H16O7
  44. The crystal structure of 2-(dimethoxymethyl)-4-(4-methylphenyl)-1H-imidazole—petroleum ether-chloroform (3/1), C27H33Cl3N4O4
  45. Crystal structure of 8-(trifluoromethyl)imidazo[1,2-a]pyridine-3-carbaldehyde, C9H5F3N2O
  46. The crystal structure of N,N-diethyl-4,6-bis(naphthalen-2-yloxy)-1,3,5-triazin-2-amine, C27H24N4O2
  47. Crystal structure of 5-bromo-7-chloro-3,3a-dihydrocyclopenta[b]chromen-1(2H)-one, C12H8BrClO2
  48. Crystal structure of 2-(bis(4-fluorophenyl)methylene)hydrazine-1-carbothioamide, C14H11F2N3S
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 10.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2018-0174/html
Scroll to top button